Monday, August 22, 2016 10:59:11 PM
1-1-14 - KW officially takes over as President of NVLX
1-30-14 - NVLX immediately acquires 14.5% equity interest in Austrianova. First vision
3-20-14 - NVLX contracts with Austrianova to encapsulate cells for clinical trials.
4-1-14 - NVLX selects TD2 to conduct preclinical and clinical studies. i.e. the mice studies-
In 3 shorts months the relationship with Austrianova is solidified and the relationship with TD2 begins.
5-1-14 - NVLX and PMCB begin preclinical studies
7-9-14 - NVLX begins studies for treatment of Ascites Fluid
8-20-14 - TD2 joins NVLX to begin studies showing that CiaB can slow the accumulation of Ascites Fluid.
9-2-14 - NVLX submits application for ODD to EMA.
10-13-14 - NVLX submits application for ODD to FDA.
10-16-14 - NVLX secures world-wide license for Insulin producing cells for Diabetes.
11-24-16 -NVLX forms Diabetes Consortium with Professor Ann Simpson
12-4-14 - NVLX announces opening of Austrianova's cGMP Live Cell Encapsulation Facility.
12-18-14 - First live cell encapsulation at new facility just 14 days after it opens.
12-22-14 - FDA grants ODD to NVLX for Pancreatic Cancer with marketing exclusivity.
This is the end of 2014 and KW has done a ton including setting the base for everything PMCB is doing today. At this time clinical trials have not been scheduled yet.
1-7-15 - NVLX changes name to PharmaCyte Biotech.
2-15-15 - PMCB initiates first preclinical study of encapsulation of cells for Diabetes.
3-18-15 - PMCB finds in addition to everything else CiaB can do it can also consistently shrink tumors.
3-27-15 - PMCB begins talking clinical trial dates.
4-10-15 - Research shows that PMCB's Melligen Cell Line can reverse Diabetes.
4-20-15 - PMCB completes formation of International Diabetes Consortium to cure Diabetes.
5-6-15 - Melligen Cells prove safe in first preclinical test in Vienna.
7-16-15 - PMCB appoints Dr. Manuel Hidalgo to Scientific Advisory Board off of his work with CiaB in the preclinical studies at TD2.
8-15-15 - Interim Audit of cGMP facility is successful.
9-9-15 - PMCB brings Imagining Endpoints on-board to assist in Radiological Imaging for Phase IIB trials
Understand clinical trials could not have started until this last step was completed. As of September, 2014, PMCB was still waiting for cGMP approval for Austrianova's facility
10-21-15 - PMCB and TD2 begin to redesign trial design.
11-17-15 - PMCB obtains ODD from EMA and additional marketing exclusivity.
The year ends without a scheduled clinical trial with at this point a number of things not completed yet.
1-4-16 - KW outlines the rest of 2016 and has been checking off that self imposed list through-out the year. This includes trial set up for late 2016.
1-25-16 - PMCB and TD2 meet to re-design of the trial design.
2-14-16 - PMCB announces that trial still on target for late 2016.
3-31-16 - PMCB and TD2 finalize trial design and is completely re-written.
4-25-16 - cGMP finally granted by Thai Government with full go-ahead. Obviously PMCB has no control over how long it takes a country's government to approve a facility like this. Clinical Trials were never starting until this was done.
Keep in mind that this approval was only granted about 4 months ago and trials are still set for late 2016.
7-14-16 - PMCB receives patent protection of melligen cells to treat Diabetes. Diabetes will begin to play a bigger role once the Phase IIB trial is underway for Pancreatic Cancer.
At this point today we await the announcement of the Principal Investigator, IND application meeting and then a date for the start of clinical trials. It's easy to blame the CEO for the pps or the needed dilution to get to this point but unfortunately when you have just one product still in clinical trials, dilution is a necessary evil. No way around it. Until CiaB proves itself in humans, it will be difficult to sell another company on it's effectiveness. So, it is do whatever it takes to get to clinical trials. And that is exactly what they are doing. Getting CiaB into clinical trials. Once those results are in, the sky is the limit for PMCB and it's shareholders. The pps is low and well-below almost everyone's cost basis. However, you never lose money until you decide to sell your shares. Be smart. Believe in the Doctors and trust that PMCB is actually in the right hands. There will be value in the pps when PMCB is in trials and then the real value will come when there are buyout rumors and then going into trials for Diabetes. Hold those shares until trials start and begin seeing a gain from your investment.
Per Angusta Ad Angusta
Per Angusta Ad Angusta
Recent PMCB News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/13/2024 08:37:40 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/29/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM